The Impact of Angiotensin-Converting Enzyme Inhibitors on Immune-Related Adverse Events and Clinical Outcomes in Patients with Metastatic NSCLC
Authors:
- Noa Shani ShremNSNoa Shani Shrem
- Samer Abu-RafeSASamer Abu-Rafe
- Abed AgbaryaAbed Agbarya
- Ashraf Abu JamaAJAshraf Abu Jama
- Asmah MiariAMAsmah Miari
- Ronen BrennerRBRonen Brenner
- Yulia DudnikYDYulia Dudnik
- Adan KhalailyAKAdan Khalaily
- Alexander YakobsonAYAlexander Yakobson
- Samer HussanySHSamer Hussany
- Raya BdairRBRaya Bdair
- Keren RouvinovKRKeren Rouvinov
Open Access
- 24 August 2026
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1882
Abstract
Background: The integration of immune checkpoint inhibitors (ICIs) has transformed metastatic non-small cell lung cancer (NSCLC) therapy. However, the immunomodulatory influence of concurrent medications, including angiotensin-converting enzyme inhibitors (ACEIs), remains poorly defined in real-world practice. Methods: This retrospective observational study included 452 patients with metastatic NSCLC treated with first-line ICI-based therapy (ICI monotherapy or chemo-immunotherapy) between 2017 and 2025. Patients were stratified according to chronic ACEI exposure, defined as administration for >2 years. Primary endpoints were overall survival (OS), progression-free survival (PFS), and immune-related adverse events (irAEs). Results: Among 452 patients, 71 (15.7%) were chronic ACEI users. ACEI use was associated with significantly longer median OS in univariable analysis (17.0 vs. 14.0 months; HR = 0.78, 95% CI: 0.61–0.99; p = 0.047) and a favorable trend toward improved PFS (14.0 vs. 11.0 months; HR = 0.81, 95% CI: 0.64–1.02; p = 0.066). ACEI users had higher rates of cutaneous rash (25.4% vs. 13.1%; p = 0.011) and transaminase elevation (29.6% vs. 8.9%; p < 0.001). Severe grade 3–5 irAEs remained uncommon and did not differ significantly between groups (p > 0.05). Conclusions: Chronic ACEI use was associated with longer OS in univariable analysis, but this association was not statistically significant after multivariable adjustment. ACEI use was also associated with increased low-grade cutaneous and hepatic toxicities without a significant increase in severe irAEs. Prospective studies are warranted to clarify the clinical significance of these associations.Keywords
This publication has 24 references indexed in Scilit:
- Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitorsNature Reviews Endocrinology, 2025
- Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockadeJournal for ImmunoTherapy of Cancer, 2024
- The new era of lung cancer therapy: Combining immunotherapy with ferroptosisCritical Reviews in Oncology/Hematology, 2024
- Treatment-related adverse events of combination chemoimmunotherapy versus chemotherapy alone in first-line treatment for non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trialsJournal of Thoracic Disease, 2024
- Exploring the Impact of ACE Inhibition in Immunity and DiseaseJournal of the Renin-Angiotensin-Aldosterone System, 2022
- Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitorsClinical Genitourinary Cancer, 2022
- Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitorsEuropean Journal of Cancer, 2022
- Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockersOncoImmunology, 2020
- Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort studyBMJ, 2018
- Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapyScience Translational Medicine, 2017